MCAS is now understood as an independent disorder in contrast to systemic or cutaneous mastocytosis. The signs and symptoms can affect the skin, the gastrointestinal tract and the cardiovascular system, for example. In a case series, clinical and paraclinical features were characterized from a cohort of MCAS patients diagnosed in the period 2022–2024.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Omaveloxolone for Friedreich's Ataxia
Efficacy and Safety Studied Over 6 Years
- Psoriasis: therapy with biologics and TYK-2-i
Progress assessments based on current long-term and real-world data
- Hypertension: the most important facts for daily practice
Early dual antihypertensive therapy is usually indicated
- Escitalopram for anxiety disorders
Positive effect, but no immediate improvement in symptoms
- Helicobacter pylori infection
Simplified dual therapy beats quadruple regimen
- Gastric carcinoma
Ways of precision oncology
- Endometrial Cancer
Immunological drivers and new therapeutic pathways
- Exercise for type 1 diabetes